ERS 2022 Highlights Podcast

In this episode, Medicom’s correspondent covers 6 presentations from the European Respiratory Society congress (ERS 2022), held in Barcelona, Spain, from 4-6 September 2022.
The topics discussed are:

1. STARR2: A new approach for treating COPD exacerbations
   Point-of-care eosinophil-guided prescription of prednisolone was non-inferior to standard-of-care prescription of prednisolone in treating COPD exacerbations, the multicentre, randomised STARR2 trial showed. A personalised endotype-based prednisolone treatment is possible for patients with COPD and should be implemented in the clinical guidelines, argued the research team.
2. Digitally enhanced therapy lowers treatment burden and costs in severe asthma
   The treatment burden for patients with severe asthma was significantly reduced by using a digital tool set informing evidence-based care, including data on medication adherence, inhaler technique, and peak flow. Importantly, the lower treatment burden in the digital care group was not associated with a hampered asthma control.
3. Head-to-head: lung volume reduction surgery vs endobronchial valves
   Lung volume reduction surgery (LVRS) was not significantly superior to bronchoscopic lung volume reduction (BLVR) with valve placement in patients with emphysema who were eligible for both treatment options. These important findings to guide treatment decisions are currently being evaluated in a larger trial.
4. Does vilobelimab reduce mortality in severe COVID-19?
   Vilobelimab may reduce mortality in patients with severe COVID-19 pneumonia, the phase 3 PANAMO trial showed. Western European patients in particular appeared to benefit from the intervention. Since vilobelimab displayed an acceptable safety profile in this population, the developers aim to discuss the results with the regulatory authorities.
5. Intravenous N-acetylcysteine performs well in hospitalized patients
   Intravenous N-acetylcysteine demonstrated mucolytic and expectorant efficacy in hospitalised patients with respiratory diseases and abnormal mucus secretion. The agent outperformed placebo in a large, randomised-controlled study.
6. Encouraging results of nintedanib in children with fibrosing ILD
   With an acceptable safety profile and promising efficacy data, nintedanib is a potential candidate for treating children and adolescents with fibrosing interstitial lung disease (ILD).

Enjoy listening!

Copyright ©2021 Medicom Medical Publishers



Posted on 22 September 202227 June 2024